JDD Webinars

Differentiating Approach to Acne Therapy: Women Vs. Men

By October 14, 2020April 22nd, 2021No Comments

Featured Article

Differentiating Approach to Acne Therapy: Women vs. Men

Join Drs. Leon H. Kircik, MD and Julie Harper, MD as they discuss Acne severity and grade (comedonal, papulopustular, mixed, nodular), skin type, presence of acne scarring and postinflammatory hyperpigmentation, menstrual cycle history (in women), and more, as well as the factors influencing treatment with classes of topical agents.

Acne vulgaris is a chronic inflammatory dermatologic disease affecting an estimated 80% of the population at some point in their life; 85% of adolescents and young adult s may experience acne and prevalent in adults with more adult women being afflicted than adult men, raising the possibility that gender difference in skin may influence the pathogenesis of acne and treatment response.
Dermatologists indicate late-onset or adult -onset acne is becoming increasingly common in women in their 20s to 50s and research shows a large number of women over age 25 have acne and the prevalence of acne remains constant until age 44 at which time there is a decrease in incidence.

FACULTY


Leon H. Kircik, MD
Clinical Professor of Dermatology
Indiana University School of Medicine
Mount Sinai Medical Center, New York, NY
Physicians Skin Care, PLLC
Louisville, KY


Julie C. Harper, MD
Clinical Associate Professor of Dermatology
University of Alabama-Birmingham
Birmingham, Alabama

Watch Now

You May Also Like

Journal of Drugs in Dermatology JDD Article about Racial Disparities in United States Clinical Trial Enrollment for Mycosis Fungoides and Sézary Syndrome

Racial Disparities in United States Clinical Trial Enrollment for Mycosis Fungoides and Sézary Syndrome

| Featured Articles, Latest News, Skin of Color | No Comments
Trials fall short on representation - Black patients underenrolled in MF/SS studies The February issue of JDD features a review of completed US interventional trials for mycosis fungoides and Sézary syndrome…
Journal of Drugs in Dermatology JDD Article about Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab. Image shows thumb and nail or patient.

Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab

| Case Reports, Featured Articles, Latest News | No Comments
Case report shows dual IL‑17A/F blockade produced striking clinical and functional gains within one month in refractory ACH The February 2026 JDD issue features a case report about a 67‑year‑old…
Journal of Drugs in Dermatology JDD Article about Oncoderm Resource Center

Oncoderm Resource Center

| Featured Articles, Latest News, Oncodermatology | No Comments
Combined Relabotulinum Toxin A frontalis modulation with NASHA™ gel skinboosters for the temples yields natural‑looking wrinkle softening and lasting skin quality gains beyond six months The Oncoderm Resource Center on…

Leave a Reply